Osteoporosis Canada is aware of the following recent media releases

1. The reported potential link between atypical fractures and bisphosphonates.

• Information on atypical fractures and bisphosphonates (PDF)

2. The reported potential link between Fosamax and atrial fibrillation.

• Information on Fosamax and atrial fibrillation (PDF)

3. The reported potential link between oral bisphosphonates and aseptic osteonecrosis.

• Information for people living with osteoporosis (PDF)
  
• Information for health care professionals (PDF)

4. The reported potential link between calcium supplement intake and vascular events.

• Information for people living with osteoporosis (PDF)
  
• Information for health care professionals (PDF)

5. Esophageal cancer and bisphosphonate use.

• We are aware of a recent publication that reports on the association between oral bisphosphonate use and esophageal cancer

6. Osteonecrosis of the Jaw.

• A number of recent medical reports have linked high doses of intravenous bisphosphonates given to patients for the treatment of multiple myeloma, breast cancer or other cancers, to a condition known as Osteonecrosis of the Jaw (ONJ)

7. The reported association between use of zoledronic acid (Aclasta) and renal impairment.

• We are aware of a recent Food and Drug Administration (FDA) publication that reports on the association between use of zoledronic acid (Aclasta) and renal impairment.

8. Osteoporosis Canada statement on FRAX®

• You may have heard recent media reports about a new fracture risk assessment tool called called FRAX®, developed by the World Health Organization (WHO).

Patients are advised to consult with their physicians concerning their individual situations if they have any questions or concerns.